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Abstract
Epsilon toxin (Etx) from Clostridium perfringens is a pore-forming protein with a lethal effect on livestock, producing severe
enterotoxemia characterized by general edema and neurological alterations. Site-specific mutations of the toxin are
valuable tools to study the cellular and molecular mechanism of the toxin activity. In particular, mutants with paired
cysteine substitutions that affect the membrane insertion domain behaved as dominant-negative inhibitors of toxin activity
in MDCK cells. We produced similar mutants, together with a well-known non-toxic mutant (Etx-H106P), as green
fluorescent protein (GFP) fusion proteins to perform in vivo studies in an acutely intoxicated mouse model. The mutant
(GFP-Etx-I51C/A114C) had a lethal effect with generalized edema, and accumulated in the brain parenchyma due to its
ability to cross the blood-brain barrier (BBB). In the renal system, this mutant had a cytotoxic effect on distal tubule
epithelial cells. The other mutants studied (GFP-Etx-V56C/F118C and GFP-Etx-H106P) did not have a lethal effect or cross the
BBB, and failed to induce a cytotoxic effect on renal epithelial cells. These data suggest a direct correlation between the
lethal effect of the toxin, with its cytotoxic effect on the kidney distal tubule cells, and the ability to cross the BBB.
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Introduction
Epsilon toxin (Etx) is the most potent clostridial toxin after
botulinum and tetanus neurotoxins. It is produced by types B and
D strains of the anaerobic bacterium Clostridium perfringens and
primarily affects livestock in the form of rapidly fatal enterotox-
emias, resulting in heavy economic losses [1]. The lethal effect of
Etx has been associated with general edema and neurological
alterations, leading to a glutamate-mediated excitotoxic effect and
neuronal death [2,3,4,5]. In addition, Etx also affects the renal
system, producing congestion, interstitial hemorrhage and cyto-
toxicity of epithelial distal tubule cells [6,7,8]. However, the
individual implication of these effects on the lethal activity of Etx is
still a matter of controversy [6,7,8,9]. There is no direct evidence
of human infections by Clostridium perfringens type B and D,
although the very low LD50 of Etx in all experimental species
tested to date suggest that this toxin might be toxic to humans
[10,11,12]. Recently, it has been postulated that Etx could
contribute to nascent Multiple Sclerosis lesion formation [13]
Etx is produced as a less toxic precursor molecule (proEtx),
which is activated upon proteolytic cleavage of amino- and
carboxy-terminal peptides [14]. Non-active proEtx presumably
binds to the same cell surface receptors as the fully active molecule
and can prevent its binding and further toxicity [7,15,16].
The most Etx-sensitive cell line known to date is the Madin-
Darby canine kidney (MDCK) cell line of epithelial origin from
the distal convoluted tubule [17]. The cytotoxic effect of Etx has
been also demonstrated in a series of cell lines and cultures of renal
origin: in a highly differentiated murine renal cortical collecting
duct principal cell line, mpkCCDcl4 [18], in the human renal
adenocarcinoma cell line ACHN [19], in the human renal
leiomyoblastoma cell line G-402 [20], and in primary cultures of
human renal tubular epithelial cells (HRTEC) [21]. In addition to
cellular models of renal origin, primary cultures of mice cerebellar
cortex granule cells are also targeted and affected by Etx [22].
Evidence based on studies using MDCK cells indicates that Etx is
a pore-forming protein that causes ion homeostasis deregulation
and cell death [23]. The toxin follows a series of steps in the cell
intoxication pathway: binding to a specific receptor on the surface
of host cells; oligomerization, forming a heptameric pre-pore
complex; and insertion into the plasma membrane producing an
active pore with the subsequent ionic deregulation and cell death
[18,22,24,25,26,27]. These three steps have been defined as
decisive in the intoxication pathway of Etx in MDCK cells
[23,26]. However, the removal of cholesterol from mpkCCDcl4
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cell membrane impairs Etx oligomerization and pore formation,
but does not block cellular ATP release and cell necrosis,
suggesting a Etx cytotoxic mechanism infdependent of pore
formation [18].
Etx mutants are valuable molecular tools to study the cellular
and molecular mechanisms of Etx activity [19,28,29,30]. Recently,
two dominant-negative inhibitors of Clostridium perfringens Etx
have been designed: Etx-I51C/A114C and Etx-V56C/F118C.
These dominant-negative mutant proteins have paired cysteine
substitutions at locations predicted to form a disulfide bond that
would impede toxin insertion into the plasma membrane and the
subsequent pore formation. Cytotoxic activity can be reconstituted
in both mutant proteins by incubation with dithiothreitol (DTT), a
reducing agent. When equimolar mixtures of wild-type Etx and
mutant proteins were added to MDCK cells, both mutant proteins
prevented wild-type Etx from forming stable oligomeric complexes
in the cells, which is a step required for pore formation and
cytotoxicity [30].
However, in vivo studies have not been performed on the
possible lethal effect of the paired cysteine mutants and their
distribution in target organs (especially kidneys and brain). Mice
have been widely used to study the effect of Etx and provide a
useful model for laboratory controlled intoxication studies
[31,32,33,34,35]. As in sheep and other naturally sensitive species,
the toxin can cross the BBB in mice and enter the brain
parenchyma [36].
We used Etx fusion proteins (wild type and mutants) with the
green-fluorescence protein (GFP-Etx, GFP-Etx-I51C/A114C and
GFP-Etx-V56C/F118C), and injected it intravenously in mice to
study their possible lethal activity and their distribution in the
target organs by direct fluorescence. A well-established non-toxic
mutant of Etx which induces protective immunity in mice [29] was
also used as a fusion protein (GFP-Etx-H106P) and compared to
Etx wild type and mutants. The results demonstrate that ability to
cross the blood-brain barrier (BBB) is related to epithelial damage
to the renal distal tubules and also with lethal effects.
Materials and Methods
Ethics statement
Male OF1 Swiss mice were housed under conventional
conditions in climatized and pathogen-free rooms with free access
to standard pelleted food and tap water. The experiments were
performed according to EU guidelines for animal experimentation
and the protocols used were approved by the University of
Barcelona’s Committee on the Ethics of Animal Experiments (Ref.
Number: 350/12). The experiments were carried out in the
animal research facility of the University of Barcelona (Campus de
Bellvitge) in animal preparation rooms with the required
equipment for isoflurane anesthesia and animal preparation. All
efforts were made to minimize suffering.
Cloning, expression and purification of GFP-Etx wild type
and mutants
Etx wild type and mutants were produced as fusion proteins
with GFP as previously described [36], starting at amino acid A47
[37], which lacks the N-terminal peptide, but not the C-terminal
peptide that was removed by trypsin digestion to produce active
toxin when required. This treatment activates Etx but does not
digest GFP. The nomenclature for the mutants follows that
previously used by Oyston et al. (1998) and Pelish and McClain
(2009). The mutations Etx-H106P [29], Etx-I51C/A114C and
Etx-V56C/F118C [30] were introduced into the cloned etxB gene
using the QuikChange multi-site-directed mutagenesis kit (Strata-
gene), following the manufacturer’s instructions and using the
primers: (59-AACTGCAACTACTACTCCTACTGTGG-
GAACTTCGA-39) for Etx-H106P, (59-AGGAAATGATTTT-
TATTGTAATAATCCTAAAGTTG-39/59-GGGAACTTCGA-
TACAATGTACTGCTAAGTTTACTG-39) for Etx-I51C/A114C,
and (59-TATTAATAATCCTAAATGTGAATTAGATGGAGAAC-
39/59-ACAAGCAACTGCTAAGTGTACTGTTCCTTTTAATG-
39) for Etx-V56C/F118C.
Wild type and mutated DNA were cloned into the pGEX-4T-1
vector (GE Healthcare Life Sciences) containing the EGFP coding
sequence to produce the corresponding recombinant fusion
proteins, as previously described [36]. All constructs were
sequenced to confirm that the mutations were introduced into
the proper positions and no errors were present. The expression of
the different proteins was induced overnight in the presence of
1 mM isopropyl beta-D-thiogalactopyranoside (IPTG) at room
temperature (RT), in 250 ml of LB medium containing 50 mg/ml
of ampicillin. Cells were pelleted and resuspended in ice cold
phosphate buffer (PB) 20 mM pH 7.5 with NaCl 250 mM,
sonicated and centrifuged at 12,0006g for 20 min. The resultant
supernatant was incubated with Glutathione Sepharose 4B beads
(GE Healthcare Life Sciences) for 1 h at 4uC. Finally, the
recombinant proteins were eluted by thrombin cleavage in
20 mM PB, pH 7.5 containing 250 mM NaCl and 2.5 mM
CaCl2. When required, wild type and mutated GFP-proEtx were
fully activated by incubation with trypsin-coated agarose beads for
30 min at RT (Sigma–Aldrich, Madrid, Spain). Protein concen-
tration was determined by the method of Bradford [38], using
bovine serum albumin (BSA) as standard. The purity of the
recombinant proteins was checked by SDS-PAGE and Coomassie
Blue staining.
Confocal microscopy on MDCK cells and mouse tissue
cryosections
MDCK cells (ATCC, CCL-34) were grown on coverslips to
confluence in DMEM-F12 medium supplemented with L-Gluta-
mine, 15 mM HEPES and antibiotics. Cells were washed three
times with PBS, and fixed with 4% paraformaldehyde (PFA) for
12 min at RT. After washing with PBS, cells were blocked by
adding PBS containing 20% normal goat serum (NGS) for 1 h at
RT and incubated with 300 nM of GFP-proEtx or GFP-proEtx
mutants in PBS containing 1% NGS for 1 h at RT. After 3 washes
with PBS, the samples were stained with TO-PRO-3 (1:1000
dilution, Molecular Probes, Invitrogen) for 7 min, washed again
and mounted with an aqueous mounting medium (Fluoromount,
SIGMA).
Incubation of MDCK cells and tissue samples with GFP-proEtx
wild type and mutants was performed according to previous
studies [6,39]. Mouse kidney and brain samples were fixed
immediately after extraction by immersion in 4% PFA for 12 h.
Samples were cryoprotected by immersion in 30% sucrose,
embedded in OCT medium and snap-frozen in precooled
isobutanol. Cryostat sections of 10 mm were obtained, mounted
onto poly-lysine coated microscope slides (Superfrost Plus,
Thermo scientific), and stored at 220uC until used. Slides were
examined in a Leica TCS-SL, spectral confocal microscope
(CCiTUB, Biology Unit of Bellvitge Campus). The relative level of
fluorescence for each condition, fusion proteins of GFP and Etx
wild type and mutants, was measured using ImageJ software
(http://rsbweb.nih.gov/ij/index.html).
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Cytotoxicity assay and protein complex formation in
MDCK cells
MDCK cells were grown to 80% confluence in DMEM F-12
medium supplemented with 10% fetal bovine serum and
antibiotics and mpkCCDc14 cells were grown in DMEM/Ham’s
F-12 (1:1, v/v) containing 60 nM sodium selenate, 5 mg/ml
transferrin, 2 mM glutamine, 50 nM dexamethasone, 1 nM
triiodothyronine, 10 ng/ml epidermal growth factor, 5 mg/ml
insulin, 20 mM D-glucose, 2% fetal calf serum, and 20 mM
HEPES, pH 7.4.
The cytotoxic activity of wild type derivatives and mutated Etx
was determined using three different assays: the propidium iodide
influx assay [40] to check the efficiency of wild type activated Etx,
the MTT assay [6], and the real-time xCELLigence impedance
analysis [41]. The propidium iodide influx assay was used to
characterize the cytotoxic activity of Etx fusion protein (with GFP)
compared to wild type toxin, while the MTT assay was used to
study the high dose-dependence of Etx mutants and the effect of
reducing agent, as previously described [30]. Values were
compared taking 0.5% of triton 6100 incubated cells as 100%
mortality and cells incubated with GFP alone as 0% of cell
mortality.
The xCELLigence System (ACEA) monitors the cellular events
in real-time by measuring electrical impedance across microelec-
trodes on the bottom of each well. In these experiments, MDCK
or mpkCCDc14 cells were seeded on E-plate 16 then treated with
or without the 10 nM of each trypsin-treated ETX sample. The
electrical impedance was measured every 15 min by RTCA-
integrated software from the xCELLigence system and derived as
a dimensionless parameter termed the cell index (CI), taking into
account the biological status of the cells (cell number, adhesion,
morphology and viability).
To analyze the formation of Etx protein complexes at the
plasma membrane, MDCK cells were grown to confluence in
10 cm plastic petri dishes and incubated with wild type and GFP-
Etx mutants, as described above.
After incubation, cells were washed once with ice-cold PBS
supplemented with protease inhibitor cocktail (Sigma) and scraped
off with a rubber policeman in 150 ml of the same buffer.
Harvested cells were lysed by one cycle of freezing and thawing
and homogenized by passage through a 29-gauge needle. Nuclei
were removed by centrifugation at 9006g for 10 min at 4uC. The
supernatant was centrifuged at 20,0006g for 30 min at 4uC and
the pellet, which was considered the crude membrane fraction,
was homogenized with ice-cold PBS supplemented with protease
inhibitor cocktail, quantified and analyzed by Western blotting
using anti-GFP rabbit polyclonal antibody.
In vivo studies in a murine model
Male OF1 Swiss mice weighing 20 g were anaesthetized by
administration of isoflurane before the intravenous injection of
GFP-Etx, GFP-proEtx or GFP-Etx mutants at a final dose of
2.5 mg/g of body weight with 200 mg BSA-Alexa 647 in PBS
containing 1% BSA. All animals injected with GFP-Etx and the
mutant GFP-Etx-I51C/A114C died between 5 and 15 min after
injection. No lethal effect was observed (up to 24 h post-injection)
with either GFP-proEtx, GFP-Etx-H106P and GFP-Etx-V56C/
F118C, and animals were routinely processed for histopathological
analysis after 15 min of i.v. injection. Each experimental
procedure was performed three times with duplicates for each
group (toxin mutant). To minimize animal suffering, mice were
anesthetized before i.v. injections and maintained under anesthesia
until the end of the experiment. Animals died as a direct result of
the intervention (Etx effect) or were sacrificed by cervical
dislocation (controls and non-toxic Etx mutants), in all cases
under deep anesthesia.
Brains and kidneys were removed, fixed by immersion in 4%
PFA for 12 h, immersed in 30% sucrose, frozen in isobutanol and
cut into 10 mm sections in a cryostat as detailed above. Some
sections were immediately mounted on slides using Immuno-
Fluore Mounting Medium (ICN Biomedicals; Costa Mesa, CA)
and examined under a Leica TCS-SL spectral confocal micro-
scope (CCiTUB, Biology Unit of the Bellvitge Campus) for direct
binding of GFP-Etx to brain and kidney samples. Alternatively,
sections were processed for immunofluorescence and confocal
microscopy. Non-specific binding was blocked by incubating the
sections in PBS containing 20% NGS and 0.2% gelatin for 1 h at
RT. The primary polyclonal anti-glial fibrillary acidic protein
(GFAP) antibody (Sigma, 1/500) was added and sections were
incubated O/N at 4uC in PBS containing 1% NGS. Alexa-546
labelled goat anti-rabbit antibody (Dako, 1/500) was used as a
secondary antibody, and incubated for 1 h before washing and
mounting the slides for confocal microscopy observation.
Results
Expression and cytotoxic characterization of
recombinant GFP-proEtx mutants
GFP-proEtx, wild type (GFP-Etx) and GFP-Etx mutants were
cloned and successfully expressed in E. coli as GST fusion
proteins. After purification and SDS-PAGE electrophoresis
analysis, fluorescent bands due to the GFP moiety of the fusion
protein were observed in a UV transilluminator. The fluorescent
bands corresponded to the Coomassie Blue stained bands of the
expected molecular size for GFP-proEtx (Figure 1A). The
cytotoxic activity of trypsin-activated tagged GFP-Etx was
compared to native Etx by the propidium iodide influx assay
(Figure 1B). Additionally, to check the cytotoxic activity of Etx
recombinant proteins (wild type and mutants) a real-time
xCELLigence impedance analysis was performed on MDCK
(Figure 1C) and mpkCDDc14 (Figure 1D) cell lines. GFP-Etx
mutants showed no cytotoxic activity at a concentration of 10 nM
compared to the wild type GFP-Etx toxin (Figure 1C and D). In
addition, to check whether a reducing agent (DTT) restores the
cytotoxic activity of the mutants with paired cysteine substitutions,
MTT assays were performed on MDCK cells exposed to 6.5 nM
of each of the GFP-Etx mutants (treated with or without DTT)
and the results were compared to those obtained with GFP-proEtx
and GFP-Etx (Figure 1E).
At this concentration, the mutant GFP-Etx-I51C/A114C did
not show any cytotoxic effect on MDCK cells unless it was
preincubated with DTT (Figure 1E). However, the GFP-Etx-
V56C/F118C and GFP-Etx-H106P mutants did not even have a
cytotoxic effect on MDCK cells when preincubated with DTT
(Figure 1E). At higher concentrations of the GFP-Etx mutants,
starting from 50 nM, mutant GFP-Etx-I51C/A114C had an
evident cytotoxic effect on MDCK cells, even in the absence of
DTT (Figure 1F). This effect contrasted with that of mutants GFP-
Etx-V56C/F118C and GFP-Etx-H106P, which did not show any
cytotoxic activity at these concentrations, even in the presence of a
reducing agent (DTT), similarly to the GFP-proEtx effect.
Binding of GFP-proEtx mutants to MDCK cells, brain and
kidney sections from mouse
Previous studies demonstrated that GFP-Etx binds with high
affinity to the plasma membrane of MDCK cells [39]. Moreover,
incubations of mouse brain and kidney sections with GFP-Etx
In Vitro and In Vivo Effects of Epsilon Toxin Mutants
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revealed that it bound to myelinic structures and to the distal and
convoluted tubules respectively [6,16,39].
To study and compare the binding properties of GFP-proEtx
wild type and mutants, MDCK cells and mouse brain and kidney
sections were incubated with the GFP-proEtx mutants, GFP-
proEtx-I51C/A114C, GFP-proEtx-V56C/F118C and GFP-
proEtx-H106P.
Similarly to wild type proEtx, incubations of MDCK cells with
the proEtx mutants revealed binding to the plasma cell membrane
(Figure 2) with no significant differences in fluorescence intensity
compared to wild type (not shown). Incubations with brain and
kidney sections revealed binding of proEtx mutants to myelinic
structures and distal tubules, respectively (Figure 3 and Figure 4).
Therefore, all of the GFP-Etx mutants tested showed a similar
binding pattern to GFP-Etx, which clearly suggests that binding to
target cells and tissues is not affected in any of the mutants.
To analyze the formation of toxin oligomers by wild type Etx
compared to Etx mutants in the plasma membrane, MDCK cells
were incubated with wild type or Etx mutants, and the presence of
Etx protein complexes was analyzed by Western blot assay
(Figure 5).
Figure 1. Characterization and cytotoxic effect of GFP-Etx-mutants. A) GFP-proEtx (1), GFP-proEtx-I51C/A114C (3), GFP-proEtx-V56C/A118C
(5) and GFP-proEtx-H106P (7) were activated by trypsin treatment to produce GFP-Etx (2), GFP-Etx-I51C/A114C (4), GFP-Etx-V56C/A118C (6) and GFP-
Etx-H106P (8). Samples were analyzed by SDS-PAGE followed by Coomassie Blue staining (CB) and direct visualization on a UV transilluminator (UV).
Note the shift in the molecular weight after trypsin activation. B) The dose-response cytotoxic effect induced by GST-GFP-ETX wild type (gray square)
was measured by the PI exclusion test and compared with native Etx (black rhombus). Results are expressed as relative fluorescence units (RFU). C
and D) Dynamic monitoring of toxin effects on MDCK (B) or mpkCCDc14 cells (C) using the xCELLigence System. Cells seeded in E-Plate16 were
incubated with 10 nM of trypsin-treated GFP-Etx (green), GFP-Etx-I51C/A114C (blue), GFP-Etx-V56C/A118C (purple) or GFP-Etx-H106P (cyan). All the
Etx mutant fusion protein-treated cells behaved similarly to the untreated control (red). Each curve is an average of n = 4. Error bars were omitted for
reasons of clarity, but never exceeded 10% of the average value. E) MDCK cells were incubated with 6.5 nM of GFP-proEtx (P), GFP-Etx (T), GFP-Etx-
I51C/A114C (M1), GFP-Etx-V56C/A118C (M2) and GFP-Etx-H106P (M3) in the presence (dark grey bars) or absence (light grey bar) of 3 mM DTT. GFP-
proEtx and GFP-Etx-H106P were used as a negative non-toxic control, whereas GFP-Etx was used as a positive control. Student’s t-test indicates
significant differences (***p,0.001) for cells incubated either with GFP-Etx or GFP-Etx-I51C/A114C after DTT treatment. F) MDCK cells were incubated
with 50 nM of GFP-proEtx (P), GFP-Etx (T), GFP-Etx-I51C/A114C (M1), GFP-Etx-V56C/A118C (M2) and GFP-Etx-H106P (M3) in the presence (dark grey
bars) or absence (light grey bar) of 3 mM DTT. GFP-proEtx and GFP-Etx-H106P were used as a negative non-toxic control, whereas GFP-Etx was used
as a positive control. Student’s t-test indicates significant differences (***p,0.001) for cells incubated either with GFP-Etx or GFP-Etx-I51C/A114C,
treated with or without DTT.
doi:10.1371/journal.pone.0102417.g001
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In vivo experimental mouse model
In a previous study, fluorescence microscopy analysis of cryostat
sections from various organs of toxin-injected mice demonstrated
specific, displaceable binding of GFP-Etx to blood vessels of brain
and to distal tubules of kidneys, and unspecific accumulation to
proximal tubules [36]. Similarly, immunofluorescence of brain
sections also identified toxin binding sites in defined regions of
mouse cerebellar cortex [22]. We therefore were interested in
determining the correlation between the observed cytotoxic
activity on MDCK cells and the distribution of wild-type and
mutant Etx in target organs (especially in brain) and the abilities of
the toxins to cross the BBB.
We first evaluated the mutant toxins for lethal effects in vivo.
Both GFP-Etx and the mutant GFP-Etx-I51C/A114C were
observed to be lethal between 5 and 15 minutes after an i.v.
injection in the mouse tail vein. The mutants GFP-Etx-V56C/
F118C and GFP-Etx-H106P did not have a lethal effect on
injected animals, at least in the first 24 h after i.v. injection, which
was the maximum post-injection time allowed before processing
the organs for histopathological analysis. Therefore, in most cases,
when GFP-Etx-mutants showed no lethal effect, animals were
processed for histopathological analysis and fluorescence distribu-
tion of the injected GFP-Etx forms, no more than 15 min after
injection.
Kidneys from GFP-Etx and GFP-Etx-I51C/A114C injected
mice revealed congested and hemorrhagic medullae compared to
animals injected with either GFP-Etx-V56C/F118C or GFP-Etx-
H106P (Figure 6E–H). Confocal images corresponding to the
fluorescence of wild type and mutated fusion proteins were
obtained from the epithelial cells of distal tubules and also in the
apical domain of epithelial proximal tubules. However, only mice
that received injections containing GFP-Etx and GFP-Etx-I51C/
A114C showed pyknotic nuclei in epithelial cells from distal
tubules (Figure 6A, C) similarly to previous observations in Etx
intoxicated animals [6], which suggests a cytotoxic effect of both
molecules on these cells. However, neither apoptotic nor necrotic
processes could be defined as a possible mechanism of cell death
after the short period of time between Etx injection and animal
death. Conversely, no alterations were observed in kidneys from
animals injected with GFP-Etx-V56C/F118C or GFP-Etx-H106P
mutants (Figure 6E,G).
Confocal images from brain sections revealed the accumulation
of GFP-Etx (Figure 7A), GFP-Etx-I51C/A114C (Figure 7B), GFP-
Etx-V56C/F118C (Figure 7C) and GFP-Etx-H106P (Figure 7D)
on the luminal surface of the vascular endothelium in all brain
areas. In the case of GFP-Etx and GFP-Etx-I51C/A114C,
fluorescence was also detected in the brain parenchyma surround-
ing some blood vessels (Figure 7A–B, arrows), which suggests that
GFP-Etx and GFP-Etx-I51C/A114C, but not GFP-Etx-V56C/
F118C and GFP-Etx-H106P, could cross the BBB. In addition, a
well-documented vasogenic edema, especially in brain microvas-
culature, that was produced by Etx (reviewed by Finnie 2004) was
Figure 2. Binding of GFP-Etx-mutants to MDCK cells. Confocal
microscopy images of MDCK cells showing the binding of GFP-Etx-
mutants to the plasma membrane (green). GFP-proEtx (A), GFP-proEtx-
I51C/A114C (B), GFP-proEtx-V56C/A118C (C) and GFP-proEtx-H106P (D).
Scale bar: 40 mm.
doi:10.1371/journal.pone.0102417.g002
Figure 3. Binding of GFP-Etx-mutants to myelinic structures
from mouse cerebellum. Confocal microscopy images showing the
binding of GFP-Etx-mutants to myelinic structures from the mouse
cerebellum. GFP-proEtx (A), GFP-proEtx-I51C/A114C (B), GFP-proEtx-
V56C/A118C (C) and GFP-proEtx-H106P (D). Scale bar corresponds to
40 mm.
doi:10.1371/journal.pone.0102417.g003
Figure 4. Binding of GFP-Etx-mutants to distal and collecting
tubules from mouse kidney. Confocal microscopy images showing
the binding of GFP-Etx-mutants to distal and collecting tubules from
the mouse kidney. GFP-proEtx (A), GFP-proEtx-I51C/A114C (B), GFP-
proEtx-V56C/A118C (C) and GFP-proEtx-H106P (D). Scale bar corre-
sponds to 40 mm.
doi:10.1371/journal.pone.0102417.g004
In Vitro and In Vivo Effects of Epsilon Toxin Mutants
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detected after GFP-Etx and GFP-Etx-I51C/A114C injection (data
not shown).
To check the integrity of the BBB in injected animals, we
performed experiments in which BSA labeled with Alexa-647 was
co-injected with the same doses of toxin or mutants indicated
above. In GFP-Etx-V56C/F118C (Figure 8 C, D) and GFP-Etx-
H106P (not shown) injected animals, green fluorescence was
associated with endothelia, as seen above, while the fluorescence
corresponding to Alexa-647-BSA (in blue), was detected inside the
blood vessels (Figure 8 C, D). In the case of GFP-Etx (not shown)
and GFP-Etx-I51C/A114C injected animals (Figure 8 A, B),
Alexa-647-BSA was confined to the vessels and surrounded by the
astrocyte’s perivascular end-feet, while GFP-Etx (not shown) and
GFP-Etx-I51C/A114C (Figure 8A, B, arrow) were clearly found
deep in the brain parenchyma. These results indicate that both
GFP-Etx and GFP-Etx-I51C/A114C not only permeabilize the
vascular endothelium, but also cross the BBB and accumulate in
the brain parenchyma.
Discussion
The present study shows that two Etx mutants designed to elude
the pore formation step in the toxin’s mechanism of action have a
differential in vivo effect but maintaining the binding and
oligomerization abilities on target cells. This is an important
finding as the cytotoxic activity of Etx has been basically associated
with its ability to oligomerize and form pores in the cell membrane
of target cells.
Etx from Clostridium perfringens crosses the blood-brain
barrier (BBB) and gets into the brain parenchyma
[36,42,43,44,45,46,47] where it produces neuronal damage by
acting on the glutamatergic system and evoking excessive release
of glutamate [4]. Moreover, it specifically binds to MDCK cells
[48] and to the epithelium of distal tubules from the kidneys,
where it produces severe kidney alterations [6,7]. We have
previously demonstrated that recombinant GFP-Etx is a conve-
nient tool to reproduce the same in vivo effects as native Etx
[6,36].
Two of the mutants of Clostridium perfringens Etx used in this
study, Etx-I51C/A114C and Etx-V56C/F118C [30], have paired
cysteine substitutions that are predicted to form a disulfide bond
that would prevent the unfolding of the loop involved in Etx
insertion into the cell membrane, a situation that may be reverted
after treatment with a reducing agent such as DTT. Etx wild type
and mutants were generated as fusion proteins with GFP, to
further detect the protein under fluorescence and confocal
microscopy. The particular behavior of each mutant was checked
first on the basis of their binding and cytotoxic effect on MDCK
cells, and afterwards by i.v. injections in mice to analyze the
impact on kidneys and brain as the main target organs. These
effects were compared with those observed for the GFP-Etx wild
type and the non-lethal GFP-Etx-H106P mutant [29]. This last
mutant does not have paired cysteine substitutions inserted or
disulfide bonds, but maintains the binding ability of the wild type
molecule and is completely non-toxic [29].
Confocal images of MDCK cells incubated with the GFP-Etx
wild type and mutants revealed that all the mutants retain the
binding ability of the native Etx to the plasma membrane.
Moreover, incubation on mouse kidneys and brain sections
showed that all Etx mutants used in this study bound to distal
tubules and myelinic structures, respectively, similarly to wild type
GFP-Etx. These results demonstrate that the paired cysteine
substitutions in the mutated Etx do not affect the binding domain
of the toxin, at least not functionally. In accordance with a
previous report [30], MTT assays on MDCK cells revealed that all
the Etx mutants were non-cytotoxic at 6.5 nM, possibly due to the
disulfide bonds that would hamper insertion of the toxin in the
plasma membrane. The effect of disulfide bonds was evident after
treatment of the mutant GFP-Etx-I51C/A114C with DTT, which
activated the mutant to the GFP-Etx wild type cytotoxic levels.
Figure 5. Oligomeric complex formation in MDCK cells treated with GFP-Etx and GFP-Etx mutants. MDCK cells were incubated with
GFP-proEtx (P), GFP-Etx (T), GFP-Etx-I51C/A114C (M1), GFP-Etx-V56C/A118C (M2) and GFP-Etx-H106P (M3) at 6.5 nM for 30 min at 37uC. GFP-Etx
mutants were previously treated (+) or not (2) with 3 mM of DTT for 1 h at 45uC. The cytotoxic effect was found only after incubations with GFP-Etx
and GFP-Etx-I51C/A114C treated with DTT (see Figure 2). Western blot analysis revealed the presence of protein complex formation (arrowhead) in all
cases except for GFP-proEtx.
doi:10.1371/journal.pone.0102417.g005
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However, DTT did not exert a significant effect on the mutant
GFP-Etx-V56C/F118C nor, as expected, on wild type and the
GFP-Etx-H106P mutant.
Curiously, MTT assays on MDCK cells incubated with GFP-
Etx mutants at 50 nM revealed a cytotoxic effect of the GFP-Etx-
I51C/A114C mutant even in the absence of DTT. However, the
GFP-Etx-V56C/F118C and GFP-Etx-H106P mutants did not
show any cytotoxic activity, even in the presence of DTT.
Although the GFP-Etx-V56C/F118C mutant remains non-toxic
even at high concentrations and in the presence of reducing
agents, it retains the ability to form protein oligomers, which
suggests that it is possible to dissociate the oligomerization step
from the subsequent pore-forming activity. This discrepancy in the
behavior of the paired cysteine Etx mutants could be explained by
the differential stability of disulfide bonds, which may be less stable
in the GFP-Etx-I51C/A114C mutant than in GFP-Etx-V56C/
F118C. It is also possible that the mutated amino acids V56 or
F118, or both, are essential for the full expression of Etx cytotoxic
activity. The ability to form protein oligomers is almost completely
Figure 6. Effect of GFP-Etx and GFP-Etx-mutants on distal and
collecting renal tubules after i.v. injection. Hematoxilin-eosin
staining (A, C, E, and G) and confocal microscopy images (B, D, F and H)
of kidney sections from mice injected with GFP-Etx (A and B), GFP-Etx-
I51C/A114C (C and D), GFP-Etx-V56C/A118C (E and F) and GFP-Etx-
H106P (G and H). All the Etx fusion proteins bind specifically to the
epithelial cells of distal and collecting renal tubules (white arrows, in
green) and unspecifically to the luminal part of proximal tubules (white
arrowheads, in green). Only the GFP-Etx and GFP-Etx-I51C/A114C
mutants produce a cytotoxic effect on epithelial cells from distal and
collecting tubules (black arrows, A and C). Scale bar correspond to
25 mm in A, C, E and G and 40 mm in B, D, F and H.
doi:10.1371/journal.pone.0102417.g006
Figure 7. Brain sections from injected mouse with GFP-Etx and
GFP-Etx-mutants. Confocal microscopy images of brain sections from
mice injected with GFP-Etx (A), GFP-Etx-I51C/A114C (B), GFP-Etx-V56C/
A118C (C) and GFP-Etx-H106P (D), and immunostained with anti-GFAP
(red). Only GFP-Etx (A) and GFP-Etx-I51C/A114C (B), could cross the
blood-brain barrier and get into the brain parenchyma (white arrows).
Scale bar corresponds to 40 mm.
doi:10.1371/journal.pone.0102417.g007
Figure 8. Brain sections from mouse co-injected with Alexa
647-labelled BSA and GFP-Etx-I51C/A114C or GFP-Etx-V56C/
A118C. Mice were i.v. injected with GFP-Etx-I51C/A114C (A–B) or GFP-
Etx-V56C/A118C (C–D) in combination with Alexa 647-labelled BSA.
Brains were processed for cryostat sectioning and examined under a
confocal microscope. Green fluorescence corresponds to GFP-Etx-I51C/
A114C (B) or GFP-Etx-V56C/A118C (D) and blue fluorescence corre-
sponds to BSA (A–D). Red fluorescence corresponds to GFAP labeling
(astrocytic processes and perivascular end-feet, A–D). Notice that in
GFP-Etx-V56C/A118C-injected mice, both BSA and the GFP-Etx mutant
remained confined in the blood vessel’s lumen surrounded by the
astrocyte’s perivascular end-feet (C and D), while in GFP-Etx-I51C/
A114C-injected mice, BSA remained in the lumen but the GFP-Etx
mutant leaked out of the vessel, beyond astrocytic processes (A and B,
arrows). Scale bars correspond to 20 mm (A and B) and 16 mm (C and D).
doi:10.1371/journal.pone.0102417.g008
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abolished in the Etx-H106P mutant, which suggests that the loss of
a cytotoxic, lethal effect is due to this mutant’s incapacity to form
the protein complex in the cell membrane previous to the pore
formation. Moreover, the proline introduced in position 106
would be responsible for this loss of activity, since substitution of
histidine-106 for serine or alanine did not produce this effect [29].
The results shown here with GFP-Etx-I51C/A114C and GFP-
Etx-V56C/F118C contrast with an earlier study [30] in which
mutant GFP-Etx-V56C/F118C had cytotoxic effects on MDCK
cells following DTT treatment. The difference in the results
between both studies could be due to divergences in the
experimental approaches that were used. These divergences
include the cell viability assay used, the time of incubation of
MDCK cells with Etx (16 h in the former study compared to
30 min in the present study), the cell culture conditions (culture
media, plates and cell density) and the recombinant protein
purification protocols. One or more of these variables may
account for the differences found between both studies, and
deciphering these variables would give an important clue to the
mechanism of action of Etx in the cytotoxic process.
The proposed model of cytotoxic action of Etx on MDCK cells
starts with its binding to the plasma membrane, followed by the
formation of complexes in the plasma membrane and formation of
a pre-pore with subsequent insertion into the membrane to form a
functional pore, which would lead to cell death [23]. Additionally,
evidence on the mechanism of action of Etx in the cell line of
collecting renal tubules mpkCCDc14 [18], indicate that pore
formation is not the only cause of cell death. Accordingly, we
cannot exclude a cytotoxic mechanism of Etx on epithelial cells
from distal tubules, which would not include the formation of a
membrane pore.
Previous in vivo studies performed by intravenous injection of
GFP-Etx in mice reproduced the proteinaceous edema and the
cytotoxic activity on the epithelial cells of renal distal tubules
induced by Etx [36]. Moreover, co-injection of GFP-Etx and
fluorescent-labeled BSA confirm that only GFP-Etx was able to
bind and cross the endothelium, and distribute far beyond the
boundaries within which BSA was confined [36]. Similar results,
compared to GFP-Etx, were observed in mice injected with the
mutant GFP-Etx-I51C/A114C, even when it was not previously
treated with DTT, and suggesting a glutamatergic effect, similar to
Etx wild type. Furthermore, in order to determine whether the
mouse serum contained a possible agent responsible for GFP-Etx-
I51C/A114C activation, MDCK cells were incubated with mouse
serum together with the GFP-Etx mutants at 6.5 nM, and no
cytotoxicity was observed (data not shown). This indicates that the
mouse serum alone is not responsible for possible activation of the
GFP-Etx-I51C/A114C. These data suggest that the mouse
toxicity found after intravenous injection of GFP-Etx-I51C/
A114C may be due to the high dose administered, which would
be in accordance with our results in MDCK cells incubated with
the GFP-Etx mutant at 50 nM or above. In contrast, the injected
GFP-Etx-V56C/F118C and GFP-Etx-H106P mutants did not
cross the BBB, produce a cytotoxic effect on epithelial cells from
distal tubules, or have a lethal effect. These results are also in
accordance with those found in MDCK cells where the Etx-
V56C/F118C and Etx-H106P mutants were not cytotoxic at any
concentration used, which strongly suggests that the lethal effect of
Etx is associated with its ability to cross the BBB and the cytotoxic
effect on renal tubules.
All together, the present report may help to understand the
toxic mechanism of one of the most potent natural toxins and
provide new clues to design molecules with therapeutic or
preventive capacity for Etx intoxication, by dissociating the
pore-forming activity from the oligomerization step in the regular
sequence of cell intoxication: binding, oligomeritzation, pore
formation, and cell death.
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